Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.0K
The pathophysiology of pneumonia involves the following steps:
4.0K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.3K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K
Atypical Pneumonia01:14

Atypical Pneumonia

17
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
17
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.2K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.0K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rare Complications in Crohn's Disease: Diagnostic and Therapeutic Challenge of Dermal Abscesses Caused by Nontuberculous Mycobacteria Following Infliximab Therapy, and Fluoroquinolone-Related Achilles Tendon Rupture.

The American journal of case reports·2026
Same author

Reply to Dissent: Guidelines for Management of Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Balance Versus Bias: Correcting Misinformation About the 2025 ATS Community-Acquired Pneumonia Guidelines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Incorporating Economic Evidence in Clinical Guidelines.

Annals of internal medicine·2026
Same author

Commensal Bacteria: An Under-recognized Cause of Pneumonia.

The Journal of infectious diseases·2026
Same author

Disseminated drug-resistant nocardiosis in a patient with advanced HIV.

IDCases·2026
Same journal

The balance between a new Antibiotic and Non-antibiotic Alternatives for the treatment and prevention of uncomplicated Urinary Tract Infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Understanding the Clone-Censor-Weight Method in Observational Studies of Antibiotic Duration.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T Cells.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Protection Against Recurrent Typhoid Fever Conferred by a Prior Episode: Evidence from a Large Cohort Study in Dhaka, Bangladesh.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Pre-treatment Gut Microbiome Diversity and Function Linked to Cytotoxic and Natural Killer Cell Immune Responses after N-803 Treatment in People with HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Reconsidering ambiguous language in infectious disease consult recommendations.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
13:27

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

49.3K

Postobstructive Pneumonia: An Underdescribed Syndrome.

Michael S Abers1, Barcleigh P Sandvall2, Rahul Sampath3

  • 1Department of Medicine, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|February 25, 2016
PubMed
Summary
This summary is machine-generated.

Postobstructive community-acquired pneumonia (PO-CAP) presents differently than bacterial pneumonia (B-CAP), with fewer bacterial causes. PO-CAP patients experienced longer symptoms and higher mortality, highlighting distinct clinical recognition and treatment needs.

Keywords:
community-acquired pneumoniapneumoniapostobstructive pneumonia

More Related Videos

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

52.6K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K

Related Experiment Videos

Last Updated: Mar 25, 2026

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
13:27

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

49.3K
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

52.6K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Postobstructive community-acquired pneumonia (PO-CAP) is a common yet poorly defined clinical syndrome.
  • The exact role of infection in PO-CAP infiltrates remains uncertain.
  • Distinguishing PO-CAP from bacterial community-acquired pneumonia (B-CAP) is crucial for effective management.

Purpose of the Study:

  • To prospectively investigate the clinical characteristics of PO-CAP.
  • To compare PO-CAP patients with a cohort of B-CAP patients.
  • To clarify the etiologic agents and clinical outcomes in PO-CAP.

Main Methods:

  • Prospective study of hospitalized community-acquired pneumonia (CAP) patients.
  • Defined PO-CAP as pulmonary infiltrate distal to an obstructed bronchus.
  • Collected sputum/blood cultures, viral PCR, urinary antigen tests, and serum procalcitonin (PCT); compared clinical and lab data between PO-CAP and B-CAP groups.

Main Results:

  • Identified 30 PO-CAP cases (5.4% of CAP); PO-CAP patients had longer symptom duration (14 vs 5 days), more weight loss, and cavitary lesions.
  • Bacterial pathogens identified in only 10% of PO-CAP cases, with low procalcitonin (PCT <0.25 ng/mL in 63.3%).
  • Despite similar severity and ICU admissions, 30-day mortality was significantly higher in PO-CAP (40.0%) versus B-CAP (11.7%).

Conclusions:

  • PO-CAP is a distinct clinical entity from B-CAP, with a low rate of bacterial etiology.
  • Findings necessitate revised clinical recognition strategies for PO-CAP.
  • Implications for understanding the role of microorganisms and optimizing antibiotic therapy in PO-CAP are significant.